Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra(TM) Clinical Trial In Neuroblastoma Patients
May 15th 2008Drug InformationEndocrinology
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that it has initiated a Phase 2a clinical trial of Azedra (Ultratrace? iobenguane I-131 or Ultratrace MIBG) for the treatment of children with high-risk neuroblastoma, a neuroendocrine cancer that primarily affects children. Azedra is already being evaluated in an ongoing dose-ranging clinical trial for pheochromocytoma in adults.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
